RESUMEN
Objective:To observe the efficacy of rosuvastatin combined with the conventional treatment in the patients with acute cerebral infarction (ACI) and the influence on the serum levels of MMp2, vasostatin-2 and sICAM-1.Methods:Totally 136 patients with ACI were randomly divided into the routine treatment group and the rosuvastatin group with 68 ones in each .The patients in the routine treatment group were treated with the conventional treatment , and those in the rosuvastatin group were treated with rosuvastatin additionally.The treatment course was 15 days.The efficacy, adverse drug reactions and the changes of MMp 2, vasostatin-2 and sI-CAM-1 in the two groups were compared .Results:The effective rate was 92.65%in rosuvastatin group and that was 77.94%in the routine treatment group, and the difference was statistically significant (P0.05).Conclusion:Rosuvastatin used in the patients with ACI has better clinical efficacy than the routine treat-ment, which can reduce the levels of MMp 2, vasostatin-2 and sICAM-1 and is worthy of clinical promotion .
RESUMEN
Objective: To clone and express the recombinant human Vasostatin120-180aa domain and to investigate its activity of inhibiting angiogenesis in CAM. Methods: After amplifying gene of human Vasostatin120-180aa domain, we sub-cloned it into pQE30 vector and expressed Vasostatin120-180aa domain by E. coli. We also tested its ability of inhibiting angiogenesis in CAM. Results: The total gene length of human Vasostatin120-180aa domain is 180 bp. Expressed by pQE30 system in E. coli and purified by IMAC, Vasostatin120-180aa was detected by SDS-PAGE, in which there is a positive band and molecular weight is about 8 kD. Conclusions: Recombinant human Vasostatin120-180aa could play effective role in anti-angiogenesis in CAM and it showed a dose dependent effect in some degree.